Showing results (311-320 of 322) with videos related to

Sort By:
Pageof 33
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 10, 2020
Risk Factors for Healthcare Personnel Infection With Endemic Coronaviruses (HKU1, OC43, NL63, 229E): Results from the Respiratory Protection Effectiveness Clinical Trial (ResPECT)Derek A T Cummings, Lewis J Radonovich, Geoffrey J Gorse, et al.
Plos Pathogens|July 18, 2022
Caspase-1-driven neutrophil pyroptosis and its role in host susceptibility to Pseudomonas aeruginosaKarin Santoni, David Pericat, Leana Gorse, et al.
The Journal of Infectious Diseases|February 1, 1996
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupJ R Mascola, S W Snyder, O S Weislow, et al.
The Journal of Experimental Medicine|August 29, 2023
EEF2-inactivating toxins engage the NLRP1 inflammasome and promote epithelial barrier disruptionMiriam Pinilla, Raoul Mazars, Romain Vergé, et al.
Vaccine|April 23, 2003
Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative studyGeoffrey J Gorse, Theresa Z O'Connor, Stephen L Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2024
Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 RetrotransposonsMarc Michel, Maryam Heidary, Anissa Mechri, et al.
The Journal of Infectious Diseases|February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection GroupB S Graham, M J McElrath, R I Connor, et al.
The Journal of Infectious Diseases|April 11, 2001
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteersR B Belshe, C Stevens, G J Gorse, et al.
Clinical and Vaccine Immunology : CVI|September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participantsSharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
The Journal of Infectious Diseases|May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann, K Weinhold, T J Matthews, et al.
Pageof 33